Business Description
Galmed Pharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011313900
Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 418.05 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 49.8 | |||||
| 3-Year EPS without NRI Growth Rate | 49.9 | |||||
| 3-Year FCF Growth Rate | 50.8 | |||||
| 3-Year Book Growth Rate | -55.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 64.97 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.36 | |||||
| 9-Day RSI | 37.59 | |||||
| 14-Day RSI | 39.63 | |||||
| 6-1 Month Momentum % | -15.28 | |||||
| 12-1 Month Momentum % | -12.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.03 | |||||
| Quick Ratio | 7.03 | |||||
| Cash Ratio | 6.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -52.5 | |||||
| Shareholder Yield % | 3.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.67 | |||||
| ROA % | -38.06 | |||||
| ROIC % | -195.97 | |||||
| ROC (Joel Greenblatt) % | -4523.33 | |||||
| ROCE % | -46.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.23 | |||||
| Price-to-Tangible-Book | 0.23 | |||||
| EV-to-EBIT | 1.16 | |||||
| EV-to-EBITDA | 1.17 | |||||
| EV-to-FCF | 1.63 | |||||
| Price-to-Net-Current-Asset-Value | 0.28 | |||||
| Price-to-Net-Cash | 0.29 | |||||
| Earnings Yield (Greenblatt) % | 86.21 | |||||
| FCF Yield % | -101.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -37.435 | ||
| Beta | -0.18 | ||
| Volatility % | 130.37 | ||
| 14-Day RSI | 39.63 | ||
| 14-Day ATR ($) | 0.342248 | ||
| 20-Day SMA ($) | 2.9915 | ||
| 12-1 Month Momentum % | -12.86 | ||
| 52-Week Range ($) | 2.68 - 23.8 | ||
| Shares Outstanding (Mil) | 1.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galmed Pharmaceuticals Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(GLMD)'s stock price today?
The current price of GLMD is $2.86. The 52 week high of GLMD is $23.80 and 52 week low is $2.68.
When is next earnings date of Galmed Pharmaceuticals Ltd(GLMD)?
The next earnings date of Galmed Pharmaceuticals Ltd(GLMD) is 2024-12-05 Est..
Does Galmed Pharmaceuticals Ltd(GLMD) pay dividends? If so, how much?
Galmed Pharmaceuticals Ltd(GLMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers